<DOC>
	<DOCNO>NCT02573324</DOCNO>
	<brief_summary>This study seek determine whether addition ABT-414 concomitant radiotherapy temozolomide ( TMZ ) prolongs progression free survival ( PFS ) overall survival ( OS ) participants newly diagnose glioblastoma ( GBM ) epidermal growth factor receptor ( EGFR ) amplification . In addition , Phase 1 , open-label , multicenter sub-study ass pharmacokinetics , safety tolerability ABT-414 subject newly diagnose EGFR-amplified GBM mild moderate hepatic impairment .</brief_summary>
	<brief_title>A Study ABT-414 Subjects With Newly Diagnosed Glioblastoma ( GBM ) With Epidermal Growth Factor Receptor ( EGFR ) Amplification</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>1 . Must clinical diagnosis Glioblastoma ( GBM ) 2 . Must confirm Epidermal growth factor receptor amplification tumor tissue 3 . Must Karnofsky Performance Status ( KPS ) performance score 70 100 ( N/A substudy ) 4 . Must recover effect surgery , postoperative infection complication surgery 5 . Must adequate bone marrow , renal , hepatic function ( For substudy , subject must adequate bone marrow renal function mildtomoderate hepatic impairment ) 1 . Multifocal , recurrent metastatic Glioblastoma ( GBM ) gliomatosis cerebri ( For substudy , subject multifocal GBM gliomatosis cerebri ca n't recurrent metastatic GBM ) 2 . Prior chemo therapy radiosensitizer head neck cancer . 3 . Prior radiotherapy head neck overlap radiation field . 4 . Prior therapy glioblastoma invasive malignancy . 5 . Prior , concomitant plan treatment NovoTTF , EGFRtargeted therapy , bevacizumab , Gliadel wafers intratumoral intracavity antineoplastic therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Newly Diagnosed Glioblastoma</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>Radiology Therapy Oncology Group</keyword>
	<keyword>ABT-414</keyword>
	<keyword>EGFRvIII</keyword>
	<keyword>Antibody Drug Conjugate</keyword>
	<keyword>Epithelial Growth Factor Receptor</keyword>
	<keyword>Brain Tumor Group</keyword>
	<keyword>Brain Tumor</keyword>
</DOC>